Answers are grounded in this paper and cite their sources.
Background Eyelashes are specialized terminal hairs with key protective and psychosocial roles. Prostaglandin F2α analogues, initially developed as ocular hypotensive agents, were observed to induce eyelash hypertrichosis, leading to their repurposing for the treatment of eyelash hypotrichosis and subsequent incorporation into prescription and over-the-counter (OTC) cosmetic serums. Objectives To provide a narrative, clinically oriented synthesis of (i) the mechanisms by which prostaglandin analogues promote eyelash growth; (ii) evidence for their efficacy and safety in idiopathic and secondary eyelash hypotrichosis; and (iii) periocular adverse effects, particularly prostaglandin-associated periorbitopathy (PAP), in the context of both prescription and cosmetic use. Methods A structured, non-systematic search of PubMed/MEDLINE, Embase and Web of Science (inception to 18 December 2025) was performed, supplemented by manual reference screening and targeted searches for regulatory and professional-society documents. Human studies of prostaglandin analogues reporting eyelash or periocular outcomes, and key mechanistic, ex vivo and regulatory sources, were narratively synthesized. Clinical studies were categorized by study design, and randomized, observational, mechanistic and regulatory evidence are reported separately. Results Randomized trials, mostly short-term and manufacturer-sponsored, show that once-daily bimatoprost 0.03% applied to the upper eyelid margin increases eyelash prominence, length, thickness and darkness in idiopathic and post-chemotherapy hypotrichosis, with limited pediatric data and mainly mild local adverse events. Evidence for latanoprost and other analogues is sparse and inconsistent. Ex vivo and in vitro data implicate the FP receptor in both anagen prolongation and inhibition of adipogenesis. Observational glaucoma data link prostaglandin exposure to PAP, with the highest risk for bimatoprost and partial reversibility, but these data cannot be transferred directly to eyelash or cosmetic use. Switching from FP agonists to the receptor-selective EP2 agonist omidenepag has been shown to reverse deepening of the upper eyelid sulcus (DUES) and lash hypertrichosis, with the latter being the least reversible sign, so the two effects could be separable. Regulatory bodies have raised safety concerns about prostaglandin-containing OTC serums. Conclusions Bimatoprost 0.03% is an effective pharmacologic enhancer of eyelash growth, but prostaglandin analogues carry a recognizable spectrum of periocular adverse effects, and long-term and cosmetic-use safety data remain limited. Careful patient selection, precise application, counselling and, where appropriate, involvement of eye-care professionals are advisable; unsupervised use of prostaglandin-containing OTC serums is not currently supported by adequate evidence.
No takes yet. Share an insight, caveat, or question.
Nagshabandi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: